{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47"}]}],"title":"Plerixafor + G-CSF"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53"}]}],"title":"Only G-CSF (no plerixafor)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"description":"Percentage of patients that required Plerixafor injection in addition to G-CSF mobilization or none at all","groups":[{"description":"Subjects will undergo mobilization and collection of HPC, Apheresis for subsequent use in various clinical protocols.\n\nFilgrastim: Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days\n\nPlerixafor: Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight\n\nApheresis: The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.","id":"OG000","title":"Hematopoietic Progenitor Cells"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"One week of mobilization therapy","title":"Percentage of Patients That Required Plerixafor + Granulocyte-colony Stimulating Factor (G-CSF) And Only G-CSF (no Plerixafor)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}